Science News

Merck & Co.’s New Cancer Drug, Lambrolizumab, Joins Gang of Breakthrough Meds

Merck & Co.’s New Cancer Drug, Lambrolizumab, Joins Gang of Breakthrough Meds
Bernadine Racoma

Merck & Co. has announced that Lambrolizumab has recently been branded a breakthrough medication. This designation is a significant milestone for this therapy for advanced melanoma from pharmaceutical giant, Merck & Co. In effect, the US Food and Drug Administration (FDA) is pushing for the development of treatment options for a life-threatening condition by giving this drug said status. The FDA is officially expediting further review and development of Lambrolizumab.

Lambrolizumab joins three experimental drugs for cancer in the exclusive “breakthrough” category. The other three are:

(1) Spalbociclib or PD-0332991 by Pfizer (for metastatic breast cancer)
(2) LDK378 by Novartis (for ALK-positive lung cancer)
(3) Ibrutinib or PCI-32765(Johnson & Johnson’s) for many different types of leukemia and lymphoma

Promising treatment for advanced melanoma

80% of the mortality rate from skin cancer is attributed to advanced melanoma, and it accounts for 1-2% of all deaths due to cancer in the United States. Lambrolizumab, the latest Merck product to receive “breakthrough therapy” designation acts by inhibiting tumor growth by using the human body’s own immune system.

Lambrolizumab or MK-3475 is currently being evaluated for its treatment value as a drug for other forms of cancer. Merck & Co. is currently at mid-stage on the clinical trials. The drug company is determining its efficacy on the management of non-small cell lung cancer.

The results of earlier studies that involved 85 patients with metastatic melanoma (inoperable) were not completely announced. But the results of the open-label, phase 1 trial are very promising with the disappearance (or complete response) of cancer in eight of the patients included in the study. However, like most medications, there are side effects from taking this drug. These include diarrhea, joint pain, fatigue, itching, and fever.

Mechanism of action

Lambrolizumab is an FDA-approved immunotherapy drug. It is currently an “investigational antibody therapy” that targets PD-1 or Programmed Death Receptor, a surface protein. PD-1 is expressed on activated T-cells and acts as inhibitory signaling receptor. In effect, Lambrolizumab increases the ability of T-cells to act on tumor cells and kill them. Compared to similar drugs that act on PD-1or its ligand, Lambrolizumab has been shown to have positive effects on human subjects.

An important milestone

The FDA grants this designation to any experimental therapy once preliminary studies demonstrate that it has the potential to demonstrate improvements over therapies that already exist. The Senior Vice-President and head of Merck & Co’s oncology franchise Gary Gilliland said that the decision of the FDA is a milestone indeed and it comes at a time when they move forward to programs in the potential of Lambrolizumab for multiple cancer indications.

According to trial investigator and director of the Melanoma Center at the Angeles Clinic and Research Institute in Los Angeles Omid Hamid, this is a good time for patients such that this development signifies a return of hope. One of the benefits of a breakthrough designation is that patients would be encouraged to take part in clinical trials and contributes to their understanding that work is still being done.

 

Comment Below

More in Science News

stone structures

Google Earth Helps Archaeologists Discover Hundreds of Ancient Stone Structures

Brian OasterOctober 24, 2017
Eclipse

The Total Solar Eclipse and Its Aftermath

Brian OasterAugust 22, 2017
Antikythera Mechanism

The Antikythera Mechanism: Astro-Time Computer Remembered

Denise RecaldeMay 17, 2017
faucet

A Solar Purification System for Contaminated Water

Brian OasterMay 4, 2017
mars-2051748_1280

Hawking Says Only 100 Years to Leave Earth for Another Planet

Denise RecaldeMay 3, 2017
cave-2196631_1280

No Bones? Ancient Human DNA Collected From Dirt

Denise RecaldeApril 27, 2017
mastomys-491576_1280

Mice Have Been Living Off Humans for Some 15,000 Years

Denise RecaldeMarch 28, 2017
dna-1903318_1280

Scientists Experiment With Storing Computer Data In DNA

Denise RecaldeMarch 2, 2017
dish

Scientists Pinpoint Galaxy That Emitted Mysterious Fast Radio Bursts

Denise RecaldeJanuary 4, 2017

Day News Corporation

415 Madison Avenue, 15th Floor, New York City, NY 10017

(212) 537-6123

Latest Tweets

DayNewsCo @DayNewsCo

Could not authenticate you.